Shares of ICON plc (NASDAQ:ICLR) have been assigned a consensus rating of “Buy” from the thirteen ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $125.40.
Several research firms recently commented on ICLR. Zacks Investment Research cut ICON from a “buy” rating to a “sell” rating in a research report on Thursday, April 19th. BidaskClub raised ICON from a “sell” rating to a “hold” rating in a research report on Thursday, April 12th. Credit Suisse Group raised ICON to a “buy” rating and set a $131.00 price objective on the stock in a research report on Friday, February 16th. Mizuho reaffirmed a “neutral” rating and set a $114.00 price objective (up from $109.00) on shares of ICON in a research report on Thursday, February 15th. Finally, ValuEngine raised ICON from a “hold” rating to a “buy” rating in a report on Tuesday, February 13th.
Shares of ICON stock traded down $1.16 during trading on Thursday, hitting $117.34. 273,965 shares of the company’s stock traded hands, compared to its average volume of 315,939. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.95 and a quick ratio of 1.95. ICON has a 1 year low of $76.81 and a 1 year high of $124.65. The stock has a market capitalization of $6,362.09, a PE ratio of 21.77, a price-to-earnings-growth ratio of 1.85 and a beta of 0.42.
ICON (NASDAQ:ICLR) last released its quarterly earnings data on Thursday, February 15th. The medical research company reported $1.43 EPS for the quarter, beating the consensus estimate of $1.41 by $0.02. ICON had a return on equity of 27.55% and a net margin of 16.01%. The company had revenue of $455.10 million for the quarter, compared to analysts’ expectations of $455.66 million. During the same period last year, the firm posted $1.33 earnings per share. ICON’s revenue was up 4.6% compared to the same quarter last year. sell-side analysts expect that ICON will post 6.02 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. WCM Investment Management CA grew its holdings in ICON by 5.8% during the 4th quarter. WCM Investment Management CA now owns 4,281,211 shares of the medical research company’s stock valued at $480,138,000 after buying an additional 233,990 shares in the last quarter. Alliancebernstein L.P. grew its holdings in ICON by 1.0% during the 4th quarter. Alliancebernstein L.P. now owns 2,560,367 shares of the medical research company’s stock valued at $287,145,000 after buying an additional 24,571 shares in the last quarter. Clearbridge Investments LLC grew its holdings in ICON by 1.0% during the 4th quarter. Clearbridge Investments LLC now owns 1,897,429 shares of the medical research company’s stock valued at $212,797,000 after buying an additional 18,041 shares in the last quarter. Renaissance Technologies LLC grew its holdings in ICON by 37.5% during the 4th quarter. Renaissance Technologies LLC now owns 1,817,307 shares of the medical research company’s stock valued at $203,811,000 after buying an additional 495,247 shares in the last quarter. Finally, Boston Partners grew its holdings in ICON by 0.5% during the 4th quarter. Boston Partners now owns 1,111,725 shares of the medical research company’s stock valued at $124,680,000 after buying an additional 5,314 shares in the last quarter. 91.09% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “ICON plc (ICLR) Receives Average Rating of “Buy” from Brokerages” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/24/icon-plc-iclr-receives-average-rating-of-buy-from-brokerages.html.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for ICON Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON and related companies with MarketBeat.com's FREE daily email newsletter.